. 2004 Aug;88(8):1069–1073. doi: 10.1136/bjo.2003.037044

Table 1.

Description of chemotherapy regimens used

Regimen 1

Week 0: cyclophosphamide: 40 mg/kg (day 1), doxorubicin 0.67 mg/kg (days 1–3), vincristine: 0.05 mg/kg (day 1).

Weeks 3, 6, 9, 12, 15, 18, 21: cyclophosphamide: 20 mg/kg (day 1), doxorubicin 0.67 mg/kg (days 1 to 3), vincristine: 0.05 mg/kg (day 1).

Weeks 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54: cyclophosphamide: 30 mg/kg (day 1), vincristine: 0.05 mg/kg (day 1).

Intrathecal chemotherapy was given on weeks 0, 1, 2, 3, 4, and 5.

Regimen 2

Weeks 0, 6, 12, 18: cyclophosphamide: 40 mg/kg (day 1), MESNA: 40 mg/kg (day 1), vincristine: 0.05 mg/kg (day 1).

Weeks 3, 9, 15, 21: carboplatin 18.7 mg/kg (patients less than 10 kg) or 560 mg/m² (more than 10 kg) (day 1), etoposide 3.3 mg/kg (less than 10 kg) or 100 mg/m² (more than10 kg) (days 1 and 2).

Regimen 3

Weeks 0, 6, 12, 18: cyclophosphamide: 65 mg/kg (day 1), MESNA: 60 mg/kg (day 1), vincristine: 0.05 mg/kg (day 1), idarubicin 10 mg/m² (day 1)

Weeks 3, 9, 15, 21: carboplatin 18.7 mg/kg (patients less than 10 kg) or 560 mg/m² (more than 10 kg) (days 1 and 2), etoposide 3.3 mg/kg (less than 10 kg) or 100 mg/m² (more than10 kg) (days 1, 2, and 3).

No intrathecal chemotherapy was prescribed in regimens 2 and 3.

Radiotherapy guidelines were: stage IIb2: orbital radiotherapy 45 Gy up to the optic chiasm (starting at week 0).

Intrathecal chemotherapy included age adjusted methotrexate, cytarabine, and dexamethasone.⁶